Breast Cancer Research and Treatment

, Volume 122, Issue 2, pp 489–493

XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: a meta-analysis

  • Li-Xin Qiu
  • Chen Mao
  • Lei Yao
  • Ke-Da Yu
  • Ping Zhan
  • Bo Chen
  • Hai-Guang Liu
  • Hui Yuan
  • Jian Zhang
  • Kai Xue
  • Xi-Chun Hu
Epidemiology

DOI: 10.1007/s10549-009-0726-1

Cite this article as:
Qiu, LX., Mao, C., Yao, L. et al. Breast Cancer Res Treat (2010) 122: 489. doi:10.1007/s10549-009-0726-1

Abstract

Published data on the association between XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer risk are inconclusive. In order to derive a more precise estimation of the relationship, a meta-analysis was performed. Crude ORs with 95% CIs were used to assess the strength of association between these polymorphisms and breast cancer risk. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. A total of four studies were involved in the meta-analysis with 6,303 cases and 6,563 controls for XRCC3 5′-UTR polymorphism and with 6,270 cases and 6,682 controls for XRCC3 IVS5-14 polymorphism. For XRCC3 5′-UTR A/G polymorphism, significantly elevated breast cancer risk was associated with variant genotype when all studies were pooled into the meta-analysis (AG vs. AA: OR = 1.11, 95% CI = 1.03–1.19; dominant model: OR = 1.09, 95% CI = 1.01–1.17). For XRCC3 IVS5-14 A/G polymorphism, significantly decreased breast cancer risk was associated with variant genotype (GG vs. AA: OR = 0.86, 95% CI = 0.77–0.96). In conclusion, this meta-analysis suggests that the variant G allele of XRCC3 5′-UTR polymorphism is a low-penetrant risk factor for developing breast cancer, while the variant G allele of XRCC3 IVS5-14 polymorphism has a protective effect on breast cancer development.

Keywords

XRCC3 Polymorphism Breast cancer Susceptibility Meta-analysis 

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Li-Xin Qiu
    • 1
    • 2
  • Chen Mao
    • 3
  • Lei Yao
    • 4
  • Ke-Da Yu
    • 2
    • 5
  • Ping Zhan
    • 6
  • Bo Chen
    • 7
  • Hai-Guang Liu
    • 8
  • Hui Yuan
    • 9
  • Jian Zhang
    • 1
    • 2
  • Kai Xue
    • 1
    • 2
  • Xi-Chun Hu
    • 1
    • 2
  1. 1.Department of Medical OncologyCancer Hospital, Fudan UniversityShanghaiChina
  2. 2.Department of OncologyShanghai Medical College, Fudan UniversityShanghaiChina
  3. 3.Department of EpidemiologySchool of Public Health and Tropical Medicine, Southern Medical UniversityGuangzhouChina
  4. 4.State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life SciencesFudan UniversityShanghaiChina
  5. 5.Breast Cancer Institute, Department of Breast SurgeryCancer Hospital, Fudan UniversityShanghaiChina
  6. 6.Department of Respiratory MedicineNanjing Chest HospitalNanjingChina
  7. 7.Department of GeriatricsFirst Affiliated Hospital, Nanjing Medical UniversityNanjingChina
  8. 8.Department of OncologyThe First Affiliated Hospital of Wenzhou Medical CollegeWenzhouChina
  9. 9.Department of Epidemiology and Biostatistics, School of Public HealthAnhui Medical UniversityAnhuiChina